Confirmation order sanctioning the Scheme of Amalgamation

Regulatory & Legal View source PDF Explain this filing

ENTERO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1217.20

prior close

₹1209.10

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.6%+2.8% vs market

Retailing peers, median of 52sector · industry level+0.7%+3.7% vs sector

On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 3.7 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.6

10m

+2.4

15m

+2.2

30m

+2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+1.6+2.8+0.7+3.7

Next day

+0.3+1.5-1.2+0.2+0.2

+0.2+0.0+0.2-0.9+1.2

-1.2-3.0+1.9-2.7+1.6

-2.9-2.4-0.5-3.2+0.3

-4.4-2.1-2.3-4.0-0.4

-2.2-3.8+1.6-4.5+2.3

15d

-1.5-0.0-1.4-3.2+1.7

-8.9-1.0-7.9-5.5-3.4

-0.6+6.5-7.1-3.7+3.1

+2.6+10.2-7.5-2.4+5.0

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 52Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Entero Healthcare Solutions Ltd has received confirmation from the Ministry of Corporate Affairs (Regional Director, Southern Region, Chennai) approving a Scheme of Amalgamation under Section 233 of the Companies Act, 2013. The scheme involves the merger of two wholly-owned subsidiaries — Chethana Pharma Distributors Private Limited and CPD Pharma Private Limited — into Rada Medisolutions Private Limited (also a wholly-owned subsidiary). The merger is via the Fast-track route, effective from April 15, 2025. The rationale includes operational efficiencies, cost reduction, elimination of corporate redundancies, and simplification of the group structure. No new shares will be issued as both transferor companies are 100% held by the transferee company. The authorized share capital of the transferee will increase to INR 1.35 crore post-merger.

Likely market impact

This is an internal restructuring consolidating wholly-owned subsidiaries. It should have minimal direct impact on Entero Healthcare's stock as the merging entities are already controlled subsidiaries. The consolidation may improve operational efficiency and reduce compliance overhead for the group.